Indications for NUPLAZID CAPSULES:
Treatment of hallucinations and delusions associated with Parkinson's disease (PD) psychosis.
34mg once daily without titration. Concomitant strong CYP3A4 inhibitors: 10mg once daily. Concomitant strong or moderate CYP3A4 inducers: avoid.
Increased mortality in elderly patients with dementia-related psychosis.
Elderly with dementia-related psychosis: increased risk of death. Not for treating patients with dementia-related psychosis unrelated to the hallucinations/delusions associated with PD psychosis. Avoid in patients with known or congenital QT prolongation, history of cardiac arrhythmias, symptomatic bradycardia, hypokalemia, or hypomagnesemia. Severe renal impairment (CrCl <30mL/min), ESRD. Pregnancy. Nursing mothers.
Potentiated by strong CYP3A4 inhibitors (eg, itraconazole, ketoconazole, clarithromycin, indinavir); see Adults. Antagonized by strong CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, St. John's wort) or moderate CYP3A4 inducers (eg, modafinil, thioridazine, efavirenz, nafcillin); see Adults. Avoid concomitant drugs known to prolong QT interval including Class 1A (eg, quinidine, procainamide, disopyramide) or Class 3 antiarrhythmics (eg, amiodarone, sotalol), certain antipsychotics (eg, ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (eg, gatifloxacin, moxifloxacin).
Peripheral edema, confusional state, nausea, hallucination, constipation, gait disturbance.